Pfizer Inc. (NYSE:PFE) will resume shipping a thyroid-disorder drug that was in short supply for the past year after a manufacturing-quality lapse prompted a recall, one of many drug shortages that have dogged the industry in recent years. Pfizer Inc. (NYSE:PFE) stock opened at $31.68 in last trading session, and closed at $31.46, trading in the range of $31.44 – $31.77. The stock showed a negative weekly performance of -0.76%.
Merck & Co (NYSE:MRK) saw some unusual options trading on Thursday. Investors bought 13,952 put options on the stock, AnalystRatingsNetwork.com reports. This represents an increase of approximately 143% compared to the typical daily volume of 5,732 put options. Merck & Co., Inc. (NYSE:MRK) shares closed at $56.03 on last trade day, by gaining 0.39%. Stock 52 week range is $42.10 – $56.34. Company’s market capitalization is $163.98 billion.
Johnson & Johnson (NYSE:JNJ)’s Cordis receives CE Mark for RENLANE Renal Denervation System to treat resistant hypertension. Cordis announced that it has received European CE Mark for its RENLANE Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The RENLANE System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency ablation system. Johnson & Johnson (NYSE:JNJ) stock decreased -0.22% and finished the last session at $91.52. The EPS of the stock remained 4.81. Company’s market capitalization is $258.22 billion.
Bristol-Myers Squibb Co (NYSE:BMY) and Pfizer (PFE) announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAFF). This subanalysis found consistent results across age groups for reducing the risk of stroke and systemic embolism and reducing the risk of all-cause death with fewer bleeding events. Owing to the higher risk at older age (age 75 and older), the absolute benefit to patients with NVAF was greater with Eliquis in the older population. These data were published in the European Heart Journal. Bristol-Myers Squibb Co (NYSE:BMY) stock opened at $53.41 in last trading session and closed at $54.14. The 52 week range of the stock is $36.31 – $56.83 and the day range was $53.38 – $54.57.
Leave a Reply